1H MR Spectroscopy* of the Breast at 1.5T and at 3T
Nouha Salibi, Ph.D.1, Marianne Vorbuchner2, Jan Ruff, Ph.D.2
1Siemens Medical Solutions, Malvern, USA. 2Siemens Medical Solutions, MREA, Erlangen, Germany | 30.05.2007
Breast 1H MRS: Monitoring response to chemotherapy
Figures 5 and 6 illustrate the use of MR spectroscopy in monitoring the effect of chemotherapy on a diagnosed invasive breast carcinoma†. Spectra were acquired following each of the 6 cycle treatment. They demonstrate a gradual reduction in the choline peak, which is hardly visible after the sixth cycle of chemotherapy. Using the Phoenix functionality of the syngo software the same measurement protocol was recalled for each follow-up examination. This insured that the same parameters were used for all measurements except for the voxel size, which was adjusted to the reduced size of the tumor.
† Courtesy of Professor T. J. Vogl, University of Frankfurt/Main, Germany.
[ 1 ] David K.W. Yeung, PhD, et al. Breast cancer: In vivo proton MR spectroscopy in the characterization of histopathologic subtypes and preliminary observations in axillary nodes metastases. Radiology, 225, pp 190–197, 2002.
[ 2 ] Rachel Katz-Brull, Philip T. Lavin, Robert E. Lenkinski. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J. Natl Cancer Inst, 94(16), pp 1197–1203, 2002.
[ 3 ] Kvistad KA, et al. Characterization of neoplastic and normal human breast tissues with In vivo 1H MR spectroscopy.
J. Magn. Reson. Imaging 10; pp 159–64, 1999.